The [South Korean] government is temporarily suspending AstraZeneca vaccines for people under 60 after a third blood clot developed in a patient after an AstraZeneca shot. Korea’s Covid-19 vaccination Task Force team said Wednesday that a medical worker in her 20s was diagnosed with blood clots in her legs and lungs twelve days after she got her first AstraZeneca jab on March 17. She developed shortness of breath on March 29. This was the third case of blood clot problems following AstraZeneca inoculations.
Previously, a blood clot was found during an autopsy of a patient in her 60s who died after inoculation. In the second case, a paramedic in his 20s was diagnosed with cerebral venous sinus thrombosis (CVST), or a brain blood clot, but he received treatment and recovered.
A woman in her 80s who received AstraZeneca Covid-19 vaccine, died in a nursing hospital in Busan. This is the first case of death in Busan after being vaccinated against Covid-19.
According to the Busan Police Agency, a woman in her 80s who received AstraZeneca vaccine died at 3:40 am on the 29th at a nursing hospital in Uam-dong, Nam-gu. The woman did not show any adverse reactions after receiving the vaccination on the 25th, but died 4 days after the vaccination. The police will conduct an autopsy to confirm the relevance of the Corona 19 vaccination.
The text of the following statement was released by the Governments of the United States of America, Australia, Canada, Czechia, Denmark, Estonia, Israel, Japan, Latvia, Lithuania, Norway, the Republic of Korea, Slovenia, and the United Kingdom.
The Governments of Australia, Canada, Czechia, Denmark, Estonia, Israel, Japan, Latvia, Lithuania, Norway, the Republic of Korea, Slovenia, the United Kingdom, and the United States of America remain steadfast in our commitment to working with the World Health Organization (WHO), international experts who have a vital mission, and the global community to understand the origins of this pandemic in order to improve our collective global health security and response. Together, we support a transparent and independent analysis and evaluation, free from interference and undue influence, of the origins of the COVID-19 pandemic. In this regard, we join in expressing shared concerns regarding the recent WHO-convened study in China, while at the same time reinforcing the importance of working together toward the development and use of a swift, effective, transparent, science-based, and independent process for international evaluations of such outbreaks of unknown origin in the future.
The mission of the WHO is critical to advancing global health and health security, and we fully support its experts and staff and recognize their tireless work to bring an end to the COVID-19 pandemic, including understanding how the pandemic started and spread. With such an important mandate, it is equally essential that we voice our shared concerns that the international expert study on the source of the SARS-CoV-2 virus was significantly delayed and lacked access to complete, original data and samples. Scientific missions like these should be able to do their work under conditions that produce independent and objective recommendations and findings. We share these concerns not only for the benefit of learning all we can about the origins of this pandemic, but also to lay a pathway to a timely, transparent, evidence-based process for the next phase of this study as well as for the next health crises.
We note the findings and recommendations, including the need for further studies of animals to find the means of introduction into humans, and urge momentum for expert-driven phase 2 studies. Going forward, there must now be a renewed commitment by WHO and all Member States to access, transparency, and timeliness. In a serious outbreak of an unknown pathogen with pandemic potential, a rapid, independent, expert-led, and unimpeded evaluation of the origins is critical to better prepare our people, our public health institutions, our industries, and our governments to respond successfully to such an outbreak and prevent future pandemics. It is critical for independent experts to have full access to all pertinent human, animal, and environmental data, research, and personnel involved in the early stages of the outbreak relevant to determining how this pandemic emerged. With all data in hand, the international community may independently assess COVID-19 origins, learn valuable lessons from this pandemic, and prevent future devastating consequences from outbreaks of disease.
We underscore the need for a robust, comprehensive, and expert-led mechanism for expeditiously investigating outbreaks of unknown origin that is conducted with full and open collaboration among all stakeholders and in accordance with the principles of transparency, respect for privacy, and scientific and research integrity. We will work collaboratively and with the WHO to strengthen capacity, improve global health security, and inspire public confidence and trust in the world’s ability to detect, prepare for, and respond to future outbreaks.
5th March 2021: South Korean health authorities are looking into six cases of deaths reported after vaccinations, adding that a potential causal relationship between the vaccinations and the deaths will be investigated.
A total of 1,578 cases of side effects after vaccinations have been reported in South Korea so far, up 860 from a day earlier, although 1,558 of them were mild symptoms.
An additional six suspected cases of anaphylactoid reaction, which has similar symptoms to anaphylaxis, a serious allergic reaction after immunization, have been reported, raising the total of such cases to 13.